Arrakis Therapeutics reduces headcount by 20%

Ar­rakis Ther­a­peu­tics has pri­or­i­tized its pipeline and re­duced its head­count by about 20% this week, the biotech’s CEO said in a state­ment to End­points News.

“We con­duct­ed a thor­ough re­view of our pipeline and have pri­or­i­tized pro­grams and ac­tiv­i­ties that we’re most ex­cit­ed about and pro­vide us with the clear­est path to de­liv­er­ing RNA-tar­get­ed small mol­e­cule med­i­cines to pa­tients,” CEO Michael Gilman wrote in an emailed state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.